source
- FDA clears Click Therapeutics' Motivista, first digital therapeutic for negative schizophrenia symptomsClick Therapeutics received FDA 510(k) clearance for its digital therapeutic, Motivista (formerly CT-155), marking the first authorized treatment targeting negative symptoms of schizophrenia in the…
- PDS Biotechnology pauses phase 3 head-and-neck trial to prioritize colorectal cancer immunotherapyPDS Biotechnology announced it is stopping work on its phase 3 head and neck cancer therapy, Versamune HPV (PDS0101), in order to reallocate resources to a different drug program. The halted trial…